TITLE

Bendamustine Outperforms R-CHOP in NHL

PUB. DATE
August 2012
SOURCE
American Health & Drug Benefits;August Special Issue 2012, Vol. 5, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a 2012 meeting of the American Society of Clinical Oncology in Chicago, Illinois, focusing on a report from the doctor Mathias J. Rummel concerning the StiL NHL1 clinical trial in which the treatment of non-Hodgkin lymphoma with bendamustine and rituximab was investigated.
ACCESSION #
84510903

 

Related Articles

  • Intrapericardial and Intrapleural Administration of Rituximab to a Patient with Marginal Zone Lymphoma. Boguradzki, Piotr; Drozd-Sokolowska, Joanna Ewa; Wieczorek, Jolanta; Kowalik, Robert; Starczewska, Marta; Krol, Maria; Kobylecka, Malgorzata; Opolski, Grzegorz; Wiktor-Jedrzejczak, Wiesław // Acta Haematologica;2013, Vol. 130 Issue 3, p169 

    The addition of rituximab to standard chemotherapy has improved the results of the treatment of B cell non-Hodgkin's lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt...

  • Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Weidmann, E.; Neumann, A.; Fauth, F.; Atmaca, A.; Al-Batran, S. E.; Pauligk, C.; Jäger, E. // Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1839 

    Background: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. However, there is very little information regarding the management of elderly patients.Patients and...

  • The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. M. J. Overman; L. Feng; B. Pro; P. McLaughlin; M. Hess; F. Samaniego; A. Younes; J. E. Romaguera; F. B. Hagemeister; L. Kwak; F. Cabanillas; M. A. Rodriguez; L. E. Fayad // Annals of Oncology;Mar2008, Vol. 19 Issue 3, p553 

    Background: The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. Patients and methods: We retrospectively reviewed the records of 45 patients with follicular grade 3 lymphoma who were treated with rituximab and the combination of...

  • Carboplatin/etoposide.  // Reactions Weekly;11/18/2006, Issue 1128, p8 

    The article presents a case report of female elderly patient who developed non-Hodgkin's lymphoma after receiving carboplatin and etoposide. The patient was diagnosed with adenocarcinoma. After remission, a mass developed on the side of her neck and she began receiving antibacterials. The mass...

  • Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Park, Y.; Lee, J.; Ryu, M.; Kim, S.; Kim, D.; Do, Y.; Lee, K.; Oh, S.; Kim, Y.; Suh, C.; Heo, D.; RYoo, B.; Kim, J.; Song, H.; Lee, W.; Kim, H.; Bang, Y.; Yang, S.; Sohn, S.; Kang, Y. // Annals of Hematology;Apr2006, Vol. 85 Issue 4, p257 

    The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination...

  • Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Samaras, Panagiotis; Heider, Helen; Haile, Sarah R.; Petrausch, Ulf; Schaefer, Niklaus G.; Siciliano, Raffaele Daniele; Meisel, Alexander; Mischo, Axel; Zweifel, Martin; Knuth, Alexander; Stenner-Liewen, Frank; Renner, Christoph // Annals of Hematology;Aug2010, Vol. 89 Issue 8, p783 

    Preclinical data indicated a detrimental effect of statins on the anti-lymphoma activity of rituximab. We evaluated the impact of concomitant statin medication on the response and survival of patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab–cyclophosphamide,...

  • Antineoplastics.  // Reactions Weekly;7/26/2008, Issue 1212, p8 

    A case study involving a 47-year-old man who experienced reactivation of hepatitis C while receiving rituximab, liposomal doxorubicin, cyclophosphamide, vincristine and prednisone for non-Hodgkin's lymphoma is presented. The clinical history of the patient, including his chemotherapy, is...

  • R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. Siddhartha, Ganguly; Vijay, Patel // Journal of Hematology & Oncology;2009, Vol. 2, p1 

    Purpose: R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used successfully in the treatment of patients with symptomatic follicular lymphoma (FL). No study has compared the...

  • Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Song, M.-K.; Chung, J.-S.; Seol, Y.-M.; Kim, S.-G.; Shin, H.-J.; Choi, Y.-J.; Cho, G.-J.; Shin, D.-H. // Annals of Oncology;Jan2010, Vol. 21 Issue 1, p140 

    Background: Rituximab has dramatic impact on outcome of patients with diffuse large B-cell lymphoma (DLBCL), especially nongerminal center (non-GC) type. A low absolute lymphocyte count (ALC) before rituximab, cyclophosphamide, vincristine, adriamycin, and prednisone (R-CHOP) therapy as a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics